This inventor holds 1 USPTO granted patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Universitätsklinikum Freiburg. Active years: 2014.
Company Filing History:
1 out of 3,688 
1 out of 36 
Years Active: 2014
Title: Stephan Mielke: Innovator in Genotyping and Toxicity Prediction
Introduction
Stephan Mielke is a notable inventor based in Loehne, Germany. He has made significant contributions to the field of pharmacogenetics, particularly in the area of microtubule-stabilizing agents. His work focuses on predicting adverse side effects in patients, which can lead to improved therapeutic outcomes.
Latest Patents
Stephan Mielke holds a patent titled "ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity." This patent outlines methods for identifying subjects who may be at an increased risk of developing adverse side effects from microtubule-stabilizing agents. The methods involve determining whether a subject possesses specific ABCB1 predictive polymorphisms, such as 2677G>T/A and 3435C>T. The presence of these polymorphisms indicates a higher likelihood of experiencing toxicity from these agents. Additionally, the patent provides methods for modifying therapy based on the identified polymorphisms, along with kits and isolated nucleic acid molecules for use in these methods. He has 1 patent to his name.
Career Highlights
Throughout his career, Stephan Mielke has worked with prominent organizations, including the United States Department of Health and Human Services and Universitätsklinikum Freiburg. His research has contributed to a better understanding of how genetic factors influence drug response and toxicity.
Collaborations
Stephan has collaborated with notable colleagues such as Klaus Mross and Dirk Behringer. Their combined expertise has furthered advancements in the field of pharmacogenetics.
Conclusion
Stephan Mielke's innovative work in genotyping and toxicity prediction has the potential to significantly enhance patient care by tailoring therapies to individual genetic profiles. His contributions to the field are invaluable and continue to influence research and clinical practices.